.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

EP. 1: Historic Perspectives on HER2+ Breast Cancer

September 24th 2020

EP. 2: Dual HER2-Targeted Approaches in Breast Cancer

September 24th 2020

EP. 3: Administration of Dual HER2-Targeted Therapy in BC

September 24th 2020

EP. 4: Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

September 24th 2020

EP. 5: Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

September 24th 2020

EP. 6: The Impact of Subcutaneous Option for HER2+ BC

September 24th 2020

EP. 7: Q&A: Practical Considerations in HER2+ Breast Cancer

September 24th 2020